A phase 2b randomized controlled trial will test whether repeated low doses of LSD (4 to 20 micrograms, taken twice weekly for 8 weeks at home) reduce depressive symptoms in people with major depressive disorder, compared to an active placebo. The trial is triple-blind and includes measures of mood, personality, sleep, brain activity, blood biomarkers, and safety. This is the first controlled trial to test microdosed LSD in patients' natural environment. Results will help determine whether psychedelic microdosing is a viable additional treatment for depression and guide future research.
Māori healthcare professionals generally support research into psychedelic-assisted therapy in Aotearoa New Zealand, but emphasize the need for cultural safety and equitable access. Interviews with 13 Māori healthcare professionals revealed four key themes: greater awareness leads to more openness toward psychedelic-assisted therapy; more research and education are needed; the therapy has potential to align with Te Ao Māori (Māori worldview); and equitable access is critical for Māori. The study used Māori health models Te Whare Tapa Whā and Te Wheke as frameworks. Improving awareness of this novel treatment is likely to influence its acceptability and cultural safety for Māori.